利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

325 条记录 (耗时 0.033 秒)

    Treatment and prevention of hepatic disorders
    41.
    发明授权
    Treatment and prevention of hepatic disorders 失效

    公开(公告)号：US5922757A

    公开(公告)日：1999-07-13

    申请号：US723052

    申请日：1996-09-30

    申请人： Mario Chojkier

    发明人： Mario Chojkier

    IPC分类号： A61K31/05 ,  A61K31/355 ,  A61K31/522 ,  C07D311/04

    CPC分类号： A61K31/355 ,  A61K31/05 ,  A61K31/522 ,  Y10S514/893 ,  Y10S514/894

    摘要： New methods are described for the treatment of viral hepatitis C involving the administration of vitamin E and other compounds with antioxidant properties. Treatment with high doses of vitamin E is effective in treating chronic hepatitis C in patients refractory to interferon. In addition, new methods are described for the treatment of hepatic fibrosis and hepatic conditions manifesting hepatic fibrosis involving the administration of butylated hydroxytoluene and a metabolite of pentoxifylline, 1-�3-carboxypropyl!-3, 7-dimethylxanthine.

    Use of plant extracts for treatment of HIV, HCV and HBV infections
    42.
    发明授权
    Use of plant extracts for treatment of HIV, HCV and HBV infections 失效
    使用植物提取物治疗HIV，HCV和HBV感染

    公开(公告)号：US5837257A

    公开(公告)日：1998-11-17

    申请号：US863803

    申请日：1997-05-27

    申请人： Hsiu-Hsien Tsai ,  Shie-Ming Hwang ,  Pai-Chu Kung

    发明人： Hsiu-Hsien Tsai ,  Shie-Ming Hwang ,  Pai-Chu Kung

    IPC分类号： A61K36/00 ,  A61K9/20 ,  A61K9/48 ,  A61K36/28 ,  A61K36/48 ,  A61K36/539 ,  A61K36/638 ,  A61K36/81 ,  A61P31/12 ,  A61P31/18 ,  A61K35/78

    CPC分类号： A61K36/00 ,  A61K36/28 ,  A61K36/48 ,  A61K36/638 ,  A61K36/81 ,  A61K9/20 ,  A61K9/48 ,  Y10S514/885 ,  Y10S514/894 ,  Y10S514/895

    摘要： This invention relates to compositions derived from Chinese herbal medicines, medicinal plants and extracts thereof, and to their use for the treatment of animals infected with viruses, especially with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). More specifically, the compositions of the present invention are derived from various Chinese herbal medicines or medicinal plants which have a long history of human consumption. The compositions of the invention are obtained through specific techniques and have demonstrated outstanding efficacy for treating human HBV carriers and hepatitic C patients. Compositions according to the invention have also exhibited in vitro antiviral activities against murine leukemia virus (MuLV) and HIV. HIV is the virus known to cause acquired immunodeficiency syndrome (AIDS) in humans and AIDS presents special problems to the medical community which the present invention addresses.

    摘要翻译： 本发明涉及中草药衍生物，药用植物及其提取物，以及用于治疗感染病毒，特别是乙型肝炎病毒（HBV），丙型肝炎病毒（HCV）和人类免疫缺陷病毒 （HIV）。 更具体地说，本发明的组合物衍生自具有长期人类消费历史的各种中草药或药用植物。 通过特定技术获得本发明的组合物，并且已经证明了治疗人类HBV携带者和肝癌C患者的突出功效。 根据本发明的组合物还显示针对鼠白血病病毒（MuLV）和HIV的体外抗病毒活性。 艾滋病毒是已知会导致人类获得性免疫缺陷综合征（AIDS）的病毒，艾滋病对本发明所涉及的医疗社区具有特殊问题。

    2-aminoethanesulfonic acid zinc complex compound
    47.
    发明授权
    2-aminoethanesulfonic acid zinc complex compound 失效
    2-氨基乙磺酸锌络合物

    公开(公告)号：US5489609A

    公开(公告)日：1996-02-06

    申请号：US356305

    申请日：1994-12-15

    申请人： Hajime Fujimura ,  Takahiro Yabuuchi ,  Teruo Tanaka ,  Yoichi Nagamura

    发明人： Hajime Fujimura ,  Takahiro Yabuuchi ,  Teruo Tanaka ,  Yoichi Nagamura

    IPC分类号： A61K31/185 ,  A61K31/315 ,  A61K33/30 ,  A61P1/04 ,  A61P1/16 ,  C07C309/14 ,  C07F3/06

    CPC分类号： C07C309/14 ,  A61K31/315 ,  Y10S514/894 ,  Y10S514/925

    摘要： The present invention covers 2-aminoethanesulfonic acid zinc complex compound as represented by the formula [I]: ##STR1## as well as a process for producing the same, and an anti-hepatitis agent, liver function improving agent and anti-ulcer agent. As compared with 2-aminoethanesulfonic acid, glutathione and glycyrrhizin, the compound (I) of the present invention exhibits improved anti-hepatitis activity, and also strengthens detoxicating activity toward various compounds to thereby develop liver function improving activity, while the said compound shows excellent anti-ulcer activity but greatly lowered toxicity.

    摘要翻译： PCT No.PCT / JP93 / 00813 Sec。 371日期1994年12月15日 102（e）日期1994年12月15日PCT提交1993年6月14日PCT公布。 公开号WO93 / 25558 日本1993年12月23日。本发明涉及式[I]表示的2-氨基乙磺酸锌络合物：及其制备方法，抗肝炎剂，肝功能改善 药剂和抗溃疡剂。 与2-氨基乙磺酸，谷胱甘肽和甘草甜素相比，本发明化合物（I）表现出改善的抗肝炎活性，并且还增强了对各种化合物的解毒活性，从而发挥肝功能改善活性，而所述化合物显示出优异的 抗溃疡活性却大大降低了毒性。

    Method and composition for testing patients with metabolic depleting diseases
    48.
    发明授权
    Method and composition for testing patients with metabolic depleting diseases 失效
    用于测试代谢性衰竭疾病患者的方法和组成

    公开(公告)号：US5320846A

    公开(公告)日：1994-06-14

    申请号：US965609

    申请日：1992-10-22

    申请人： Bruce R. Bistrian ,  John D. Palombo

    发明人： Bruce R. Bistrian ,  John D. Palombo

    IPC分类号： A61K9/00 ,  A61K47/00

    CPC分类号： A61K9/0029 ,  A61K31/70 ,  Y10S514/838 ,  Y10S514/893 ,  Y10S514/894

    摘要： A method of treating patients with clinical disorder involving splanchnic disorders such as liver or gut dysfunction, the dysfunction being characterized by depletion of metabolic energy sources. The treatment involves the step of administering an effective amount of adenosine, or related nucleosides, to achieve and/or maintain normal metabolic levels of adenosine triphosphate (ATP) and/or its precursors in the patient's liver or other splanchnic organs. Administration may be as a total enteral nutritional diet, or as a dietary supplement. The invention includes a total enteral nutrition diet having nutritionally acceptable amounts of a lipid source, a protein source, a carbohydrate source, a vitamin source, and a mineral source, and an effective amount of adenosine to achieve normal metabolic levels of ATP and/or its precursors in ATP deficient organs of a recipient host.

    摘要翻译： 一种治疗涉及内脏病例如肝脏或肠道功能障碍的临床病症的患者的方法，其功能障碍的特征在于代谢能源的消耗。 治疗涉及施用有效量的腺苷或相关核苷以达到和/或维持患者肝脏或其它内脏器官中三磷酸腺苷（ATP）和/或其前体的正常代谢水平的步骤。 管理可能是一种全面的肠内营养饮食，或作为膳食补充剂。 本发明包括具有营养可接受量的脂质源，蛋白质来源，碳水化合物源，维生素源和矿物源的总肠内营养饮食和有效量的腺苷以实现ATP和/或的正常代谢水平 其前体在受体宿主的ATP缺乏器官中。

    Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
    50.
    发明授权
    Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides 失效
    包含5-取代嘧啶核苷的抗病毒药物组合物

    公开(公告)号：US5215971A

    公开(公告)日：1993-06-01

    申请号：US726738

    申请日：1991-07-02

    申请人： Roelf Datema ,  Kristina B. Gotthammar ,  Karl N. G. Johansson ,  Zsuzsanna M. I. Kovacs ,  Bjorn G. Lindborg ,  Goran B. Stening ,  Bo F. berg

    发明人： Roelf Datema ,  Kristina B. Gotthammar ,  Karl N. G. Johansson ,  Zsuzsanna M. I. Kovacs ,  Bjorn G. Lindborg ,  Goran B. Stening ,  Bo F. berg

    IPC分类号： C07H19/06

    CPC分类号： A61K31/70 ,  C07H19/06 ,  Y10S514/894

    摘要： Use of a compound of the formula ##STR1## wherein A is .beta.-2'-deoxy-D-ribofuranosyl or .beta.-D-arabinofuranosyl;R.sup.1 is hydroxy or amino;R.sup.2 is cycloalkyl or alkyl-substituted cycloalkyl containing 1-5 carbon atoms; saturated or unsaturated, straight or branched alkyl containing 1-5 carbon atoms which may be unsubstituted or substituted with halogen, hydroxy, mercapto, trifluoroalkyl or difluoroalkyl containing 1-3 carbon atoms, phenoxy or alkoxy containing 1-3 carbon atoms; phenyl or phenylalkyl containing 1-3 carbon atoms in the alkyl part, or a physiologically acceptable salt thereof,for manufacture of a medicament for therapeutic or prophylactic control or treatment of retrovirus, especially HIV, or hepatitis B virus infections in animal and man and to a method of such treatment.

    摘要翻译： 使用下式的化合物其中A为β-2'-脱氧-D-呋喃核糖基或β-D-阿拉伯呋喃糖基; R1是羟基或氨基; R2是环烷基或含1-5个碳原子的烷基取代的环烷基; 含有1-5个碳原子的饱和或不饱和的直链或支链烷基，其可以是未取代的或被含有1-3个碳原子的卤素，羟基，巯基，三氟烷基或二氟烷基取代，苯氧基或含有1-3个碳原子的烷氧基; 在烷基部分含有1-3个碳原子的苯基或苯基烷基或其生理上可接受的盐，用于制备用于治疗或预防性控制或治疗动物和人类的逆转录病毒，特别是HIV或乙型肝炎病毒感染的药物，以及 这种治疗方法。